Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy

D. L. Mayers; A. J. Japour; J. M. Arduino; S. M. Hammer; R. Reichman; K. F. Wagner; R. Chung; J. Lane; C. S. Crumpacker; G. X. McLeod; Laurel A Beckett; C. R. Roberts; D. Winslow; D. Burke; N. Ruiz; M. Fujimara-Justice; P. Kernozek; J. Koch; C. Brewer

Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy

D. L. Mayers, A. J. Japour, J. M. Arduino, S. M. Hammer, R. Reichman, K. F. Wagner, R. Chung, J. Lane, C. S. Crumpacker, G. X. McLeod, Laurel A Beckett, C. R. Roberts, D. Winslow, D. Burke, N. Ruiz, M. Fujimara-Justice, P. Kernozek, J. Koch, C. Brewer

Research output: Contribution to journal › Article › peer-review

59 Scopus citations

Abstract

Human immunodeficiency virus type 1 (HIV-1) isolates resistant to zidovudine (ZDV) have previously been demonstrated to exhibit in vitro cross- resistance to other similar dideoxynucleoside agents which contain a 3'- azido group. However, cross-resistance to didanosine (ddI) or dideoxycytidine (ddC) has been less well documented. ZDV, ddI, and ddC susceptibility data have been collected from clinical HIV-1 isolates obtained by five clinical centers and their respective retrovirology laboratories. All subjects were treated only with ZDV. Clinical HIV-1 isolates were isolated, amplified, and assayed for drug susceptibility in standardized cultures of phytohemagglutinin-stimulated donor peripheral blood mononuclear cells obtained from healthy seronegative donors. All five cohorts showed a correlation between decreased in vitro susceptibility to ZDV and decreased susceptibility to ddI and ddC. For each 10-fold decrease in ZDV susceptibility, an average corresponding decrease of 2.2-fold in ddI susceptibility was observed (129 isolates studied; P < 0.001, Fisher's test of combined significance). Similarly, susceptibility to ddC decreased 2.0- fold for each 10-fold decrease in ZDV susceptibility (82 isolates studied; P < 0.001, Fisher's test of combined significance). These data indicate that a correlation exists between HIV-1 susceptibilities to ZDV and ddI or ddC for clinical HIV-1 isolates.

Original language	English (US)
Pages (from-to)	307-314
Number of pages	8
Journal	Antimicrobial Agents and Chemotherapy
Volume	38
Issue number	2
State	Published - 1994
Externally published	Yes

ASJC Scopus subject areas

Pharmacology (medical)

Access to Document

Fingerprint Dive into the research topics of 'Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy'. Together they form a unique fingerprint.

Cite this

Mayers, D. L., Japour, A. J., Arduino, J. M., Hammer, S. M., Reichman, R., Wagner, K. F., Chung, R., Lane, J., Crumpacker, C. S., McLeod, G. X., Beckett, L. A., Roberts, C. R., Winslow, D., Burke, D., Ruiz, N., Fujimara-Justice, M., Kernozek, P., Koch, J., & Brewer, C. (1994). Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. Antimicrobial Agents and Chemotherapy, 38(2), 307-314.

Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. / Mayers, D. L.; Japour, A. J.; Arduino, J. M.; Hammer, S. M.; Reichman, R.; Wagner, K. F.; Chung, R.; Lane, J.; Crumpacker, C. S.; McLeod, G. X.; Beckett, Laurel A; Roberts, C. R.; Winslow, D.; Burke, D.; Ruiz, N.; Fujimara-Justice, M.; Kernozek, P.; Koch, J.; Brewer, C.

In: Antimicrobial Agents and Chemotherapy, Vol. 38, No. 2, 1994, p. 307-314.

Research output: Contribution to journal › Article › peer-review

Mayers, DL, Japour, AJ, Arduino, JM, Hammer, SM, Reichman, R, Wagner, KF, Chung, R, Lane, J, Crumpacker, CS, McLeod, GX, Beckett, LA, Roberts, CR, Winslow, D, Burke, D, Ruiz, N, Fujimara-Justice, M, Kernozek, P, Koch, J & Brewer, C 1994, 'Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy', Antimicrobial Agents and Chemotherapy, vol. 38, no. 2, pp. 307-314.

Mayers, D. L. ; Japour, A. J. ; Arduino, J. M. ; Hammer, S. M. ; Reichman, R. ; Wagner, K. F. ; Chung, R. ; Lane, J. ; Crumpacker, C. S. ; McLeod, G. X. ; Beckett, Laurel A ; Roberts, C. R. ; Winslow, D. ; Burke, D. ; Ruiz, N. ; Fujimara-Justice, M. ; Kernozek, P. ; Koch, J. ; Brewer, C. / Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. In: Antimicrobial Agents and Chemotherapy. 1994 ; Vol. 38, No. 2. pp. 307-314.

@article{58b52cac57b84fe18d35c71401047038,

title = "Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy",

abstract = "Human immunodeficiency virus type 1 (HIV-1) isolates resistant to zidovudine (ZDV) have previously been demonstrated to exhibit in vitro cross- resistance to other similar dideoxynucleoside agents which contain a 3'- azido group. However, cross-resistance to didanosine (ddI) or dideoxycytidine (ddC) has been less well documented. ZDV, ddI, and ddC susceptibility data have been collected from clinical HIV-1 isolates obtained by five clinical centers and their respective retrovirology laboratories. All subjects were treated only with ZDV. Clinical HIV-1 isolates were isolated, amplified, and assayed for drug susceptibility in standardized cultures of phytohemagglutinin-stimulated donor peripheral blood mononuclear cells obtained from healthy seronegative donors. All five cohorts showed a correlation between decreased in vitro susceptibility to ZDV and decreased susceptibility to ddI and ddC. For each 10-fold decrease in ZDV susceptibility, an average corresponding decrease of 2.2-fold in ddI susceptibility was observed (129 isolates studied; P < 0.001, Fisher's test of combined significance). Similarly, susceptibility to ddC decreased 2.0- fold for each 10-fold decrease in ZDV susceptibility (82 isolates studied; P < 0.001, Fisher's test of combined significance). These data indicate that a correlation exists between HIV-1 susceptibilities to ZDV and ddI or ddC for clinical HIV-1 isolates.",

author = "Mayers, {D. L.} and Japour, {A. J.} and Arduino, {J. M.} and Hammer, {S. M.} and R. Reichman and Wagner, {K. F.} and R. Chung and J. Lane and Crumpacker, {C. S.} and McLeod, {G. X.} and Beckett, {Laurel A} and Roberts, {C. R.} and D. Winslow and D. Burke and N. Ruiz and M. Fujimara-Justice and P. Kernozek and J. Koch and C. Brewer",

year = "1994",

language = "English (US)",

volume = "38",

pages = "307--314",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "2",

}

TY - JOUR

T1 - Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy

AU - Mayers, D. L.

AU - Japour, A. J.

AU - Arduino, J. M.

AU - Hammer, S. M.

AU - Reichman, R.

AU - Wagner, K. F.

AU - Chung, R.

AU - Lane, J.

AU - Crumpacker, C. S.

AU - McLeod, G. X.

AU - Beckett, Laurel A

AU - Roberts, C. R.

AU - Winslow, D.

AU - Burke, D.

AU - Ruiz, N.

AU - Fujimara-Justice, M.

AU - Kernozek, P.

AU - Koch, J.

AU - Brewer, C.

PY - 1994

Y1 - 1994

N2 - Human immunodeficiency virus type 1 (HIV-1) isolates resistant to zidovudine (ZDV) have previously been demonstrated to exhibit in vitro cross- resistance to other similar dideoxynucleoside agents which contain a 3'- azido group. However, cross-resistance to didanosine (ddI) or dideoxycytidine (ddC) has been less well documented. ZDV, ddI, and ddC susceptibility data have been collected from clinical HIV-1 isolates obtained by five clinical centers and their respective retrovirology laboratories. All subjects were treated only with ZDV. Clinical HIV-1 isolates were isolated, amplified, and assayed for drug susceptibility in standardized cultures of phytohemagglutinin-stimulated donor peripheral blood mononuclear cells obtained from healthy seronegative donors. All five cohorts showed a correlation between decreased in vitro susceptibility to ZDV and decreased susceptibility to ddI and ddC. For each 10-fold decrease in ZDV susceptibility, an average corresponding decrease of 2.2-fold in ddI susceptibility was observed (129 isolates studied; P < 0.001, Fisher's test of combined significance). Similarly, susceptibility to ddC decreased 2.0- fold for each 10-fold decrease in ZDV susceptibility (82 isolates studied; P < 0.001, Fisher's test of combined significance). These data indicate that a correlation exists between HIV-1 susceptibilities to ZDV and ddI or ddC for clinical HIV-1 isolates.

AB - Human immunodeficiency virus type 1 (HIV-1) isolates resistant to zidovudine (ZDV) have previously been demonstrated to exhibit in vitro cross- resistance to other similar dideoxynucleoside agents which contain a 3'- azido group. However, cross-resistance to didanosine (ddI) or dideoxycytidine (ddC) has been less well documented. ZDV, ddI, and ddC susceptibility data have been collected from clinical HIV-1 isolates obtained by five clinical centers and their respective retrovirology laboratories. All subjects were treated only with ZDV. Clinical HIV-1 isolates were isolated, amplified, and assayed for drug susceptibility in standardized cultures of phytohemagglutinin-stimulated donor peripheral blood mononuclear cells obtained from healthy seronegative donors. All five cohorts showed a correlation between decreased in vitro susceptibility to ZDV and decreased susceptibility to ddI and ddC. For each 10-fold decrease in ZDV susceptibility, an average corresponding decrease of 2.2-fold in ddI susceptibility was observed (129 isolates studied; P < 0.001, Fisher's test of combined significance). Similarly, susceptibility to ddC decreased 2.0- fold for each 10-fold decrease in ZDV susceptibility (82 isolates studied; P < 0.001, Fisher's test of combined significance). These data indicate that a correlation exists between HIV-1 susceptibilities to ZDV and ddI or ddC for clinical HIV-1 isolates.

UR - http://www.scopus.com/inward/record.url?scp=0028089170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028089170&partnerID=8YFLogxK

M3 - Article

C2 - 8192457

AN - SCOPUS:0028089170

VL - 38

SP - 307

EP - 314

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

ER -